Want to see IN:LINCOLN full AI Analyst Report?
Top Page
Lincoln Pharmaceuticals Ltd
(LINCOLN)
Select Model
Select Model
Rating:78Outperform
Price Target:
₹705.00
▲(14.53% Upside)
Action:Reiterated
Date:09/06/26
The score is driven primarily by strong financial strength (very low leverage, solid profitability, and improved FY2026 cash flow), tempered by margin compression and some historical cash-flow volatility. Technicals are neutral-to-mildly positive, and valuation appears reasonable on earnings (P/E 12.89) though the dividend yield is minimal.
Positive Factors
Conservative balance sheet
Debt-to-equity of ~0.006 and a large equity base provide durable financial flexibility. Low leverage reduces refinancing and interest-rate risk, supports capex, M&A or downturn resilience, and meaningfully lowers bankruptcy risk versus peers with higher debt profiles.
Negative Factors
Margin compression
Notable compression across gross, operating and EBITDA margins signals structural pressure from higher input costs or weaker product mix. If persistent, this erodes operating leverage, limits reinvestment capacity and could cap long-term profit expansion absent pricing power or cost actions.
Read all positive and negative factors
Positive Factors
Negative Factors
Conservative balance sheet
Debt-to-equity of ~0.006 and a large equity base provide durable financial flexibility. Low leverage reduces refinancing and interest-rate risk, supports capex, M&A or downturn resilience, and meaningfully lowers bankruptcy risk versus peers with higher debt profiles.
Read all positive factors
Lincoln Pharmaceuticals Ltd (LINCOLN) vs. iShares MSCI India ETF (INDA)
Market Cap
₹12.52B
Dividend Yield0.29%
Average Volume (3M)4.92K
Price to Earnings (P/E)12.9
Beta (1Y)1.06
Revenue Growth10.20%
EPS Growth11.70%
CountryIN
Employees1,352
SectorGeneral
Sector StrengthN/A
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)48.16
Shares Outstanding20,029,728
10 Day Avg. Volume4,976
30 Day Avg. Volume4,919
Financial Highlights & Ratios
PEG Ratio1.91
Price to Book (P/B)1.49
Price to Sales (P/S)1.69
P/FCF Ratio13.88
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)72
Revenue Forecast (FY)₹8.82B
Lincoln Pharmaceuticals Ltd Business Overview & Revenue Model
Company Description
Lincoln Pharmaceuticals Limited, established in 1979 and headquartered in Ahmedabad, India, is a pharmaceutical company engaged in the manufacturing and global distribution of its products. Its comprehensive product line addresses a wide array of ...
How the Company Makes Money
Lincoln Pharmaceuticals primarily makes money by selling pharmaceutical formulations (finished-dose medicines) under branded and/or branded-generic portfolios. Revenue is generated from (1) domestic sales in India through prescriptions and trade c...
Lincoln Pharmaceuticals Ltd Financial Statement Overview
Summary
Income Statement
74
Positive
Balance Sheet
90
Very Positive
Cash Flow
78
Positive
| Breakdown | TTM | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 7.19B | 6.71B | 6.23B | 5.81B | 5.05B | 4.68B |
| Gross Profit | 2.87B | 2.20B | 3.32B | 2.97B | 2.59B | 2.46B |
| EBITDA | 1.28B | 1.31B | 1.24B | 1.34B | 1.12B | 1.05B |
| Net Income | 964.53M | 878.94M | 823.46M | 933.05M | 728.99M | 693.55M |
Balance Sheet | ||||||
| Total Assets | 0.00 | 8.90B | 7.97B | 7.00B | 5.87B | 5.34B |
| Cash, Cash Equivalents and Short-Term Investments | 2.41B | 2.41B | 1.96B | 1.52B | 1.14B | 1.15B |
| Total Debt | 0.00 | 44.22M | 0.00 | 10.67M | 19.97M | 20.44M |
| Total Liabilities | -7.58B | 1.33B | 1.25B | 1.07B | 849.46M | 1.01B |
| Stockholders Equity | 7.58B | 7.58B | 6.72B | 5.93B | 5.02B | 4.33B |
Cash Flow | ||||||
| Free Cash Flow | 390.02M | 815.07M | 737.71M | 237.41M | 249.80M | 306.07M |
| Operating Cash Flow | 497.63M | 1.07B | 930.15M | 632.17M | 392.62M | 761.32M |
| Investing Cash Flow | -422.12M | -996.37M | -789.47M | -573.42M | -366.43M | -780.80M |
| Financing Cash Flow | -6.86M | 8.16M | -64.02M | -51.80M | -45.01M | -25.56M |
Lincoln Pharmaceuticals Ltd Technical Analysis
Positive
615.55
Price Trends
605.26
Positive
626.00
Negative
580.37
Positive
Market Momentum
7.20
Negative
55.02
Neutral
66.17
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:LINCOLN, the sentiment is Positive. The current price of 615.55 is below the 20-day moving average (MA) of 619.17, above the 50-day MA of 605.26, and above the 200-day MA of 580.37, indicating a bullish trend. The MACD of 7.20 indicates Negative momentum. The RSI at 55.02 is Neutral, neither overbought nor oversold. The STOCH value of 66.17 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IN:LINCOLN.
Lincoln Pharmaceuticals Ltd Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
78 Outperform | ₹12.52B | 12.89 | ― | 0.29% | 10.20% | 11.70% | |
78 Outperform | ₹15.39B | 34.32 | ― | 1.71% | 3.87% | -25.38% | |
74 Outperform | ₹21.82B | 18.54 | ― | 0.62% | 20.87% | 116.29% | |
70 Outperform | ₹18.34B | 21.53 | ― | 0.51% | 0.44% | 48.60% | |
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% | |
51 Neutral | ₹33.58B | 57.04 | ― | 1.14% | 113.34% | -80.12% | |
49 Neutral | ₹8.37B | 13.82 | ― | 1.20% | 3.63% | 24.22% |
* General Sector Average
IN:LINCOLN
Lincoln Pharmaceuticals Ltd
625.05
72.52
13.12%
IN:INDSWFTLAB
Ind-Swift Laboratories Ltd.
386.10
278.72
259.56%
IN:JAGSNPHARM
Jagsonpal Pharmaceuticals Ltd.
233.40
-12.63
-5.13%
IN:SYNCOMF
Syncom Formulation (India) Ltd.
19.51
1.68
9.42%
IN:VENUSREM
Venus Remedies Limited
1,632.25
1,183.09
263.40%
IN:WANBURY
Wanbury Limited
239.50
-16.70
-6.52%
Lincoln Pharmaceuticals Ltd Corporate Events
Lincoln Pharmaceuticals sets September 30 virtual AGM, proposes dividend and director re-appointments
Sep 5, 2026
Lincoln Pharmaceuticals Ltd has scheduled its 32nd Annual General Meeting for September 30, 2026, at 11:00 a.m. IST, to be conducted via video conferencing or other audio-visual means, with the registered office in Ahmedabad deemed as the venue. T...
Lincoln Pharmaceuticals files SEBI demat compliance certificate for June quarter
Jul 6, 2026
Lincoln Pharmaceuticals Ltd has submitted to the National Stock Exchange of India and BSE a quarterly confirmation certificate under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018 for the period ended June 30, 2026....
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.